A citation-based method for searching scientific literature

Tarinee Manchana, Natacha Phoolcharoen, Patou Tantbirojn. Gynecol Oncol Rep 2019
Times Cited: 21







List of co-cited articles
116 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Inherited Mutations in Women With Ovarian Carcinoma.
Barbara M Norquist, Maria I Harrell, Mark F Brady, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Qian Yi, Robert A Burger,[...]. JAMA Oncol 2016
377
28

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
743
28

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
994
23

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Tuya Pal, Jenny Permuth-Wey, Judith A Betts, Jeffrey P Krischer, James Fiorica, Hector Arango, James LaPolla, Mitchell Hoffman, Martin A Martino, Katie Wakeley,[...]. Cancer 2005
512
23

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
23

The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients.
Xiaohua Wu, Lingying Wu, Beihua Kong, Jihong Liu, Rutie Yin, Hao Wen, Ning Li, Hualei Bu, Yanling Feng, Qingli Li,[...]. Int J Gynecol Cancer 2017
38
23

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
23

The contribution of BRCA1 and BRCA2 to ovarian cancer.
Susan J Ramus, Simon A Gayther. Mol Oncol 2009
114
23

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
978
23

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
461
23

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
544
23

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
M Moschetta, A George, S B Kaye, S Banerjee. Ann Oncol 2016
109
19


Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
19

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
724
19

Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
19

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
830
19

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael Friedlander, Aikou Okamoto, Kathleen N Moore, Noa Efrat Ben-Baruch, Theresa L Werner,[...]. N Engl J Med 2019
315
19

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Darren R Hodgson, Brian A Dougherty, Zhongwu Lai, Anitra Fielding, Lynda Grinsted, Stuart Spencer, Mark J O'Connor, Tony W Ho, Jane D Robertson, Jerry S Lanchbury,[...]. Br J Cancer 2018
96
19

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.
Shiyu Zhang, Robert Royer, Song Li, John R McLaughlin, Barry Rosen, Harvey A Risch, Isabel Fan, Linda Bradley, Patricia A Shaw, Steven A Narod. Gynecol Oncol 2011
252
19

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
19

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
Kelly L Bolton, Georgia Chenevix-Trench, Cindy Goh, Siegal Sadetzki, Susan J Ramus, Beth Y Karlan, Diether Lambrechts, Evelyn Despierre, Daniel Barrowdale, Lesley McGuffog,[...]. JAMA 2012
384
14

Homologous recombination deficiency and ovarian cancer.
Jonathan A Ledermann, Yvette Drew, Rebecca S Kristeleit. Eur J Cancer 2016
110
14

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
14

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley,[...]. Lancet Oncol 2017
643
14

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Timothy R Rebbeck, Nandita Mitra, Fei Wan, Olga M Sinilnikova, Sue Healey, Lesley McGuffog, Sylvie Mazoyer, Georgia Chenevix-Trench, Douglas F Easton, Antonis C Antoniou,[...]. JAMA 2015
273
14

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
14

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Bryan T J Hennessy, Kirsten M Timms, Mark S Carey, Alexander Gutin, Larissa A Meyer, Darl D Flake, Victor Abkevich, Jennifer Potter, Dmitry Pruss, Pat Glenn,[...]. J Clin Oncol 2010
256
14

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
Renata Rodrigues da Cunha Colombo Bonadio, Rodrigo Nogueira Fogace, Vanessa Costa Miranda, Maria Del Pilar Estevez Diz. Clinics (Sao Paulo) 2018
41
14

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
910
14

The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE).
Takayuki Enomoto, Daisuke Aoki, Kana Hattori, Masahisa Jinushi, Junzo Kigawa, Nobuhiro Takeshima, Hitoshi Tsuda, Yoh Watanabe, Kosuke Yoshihara, Toru Sugiyama. Int J Gynecol Cancer 2019
33
14

Hereditary ovarian cancer: not only BRCA 1 and 2 genes.
Angela Toss, Chiara Tomasello, Elisabetta Razzaboni, Giannina Contu, Giovanni Grandi, Angelo Cagnacci, Russell J Schilder, Laura Cortesi. Biomed Res Int 2015
91
14

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.
Neil Senzer, Minal Barve, Joseph Kuhn, Anton Melnyk, Peter Beitsch, Martin Lazar, Samuel Lifshitz, Mitchell Magee, Jonathan Oh, Susan W Mill,[...]. Mol Ther 2012
113
14

Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Jonathan Oh, Minal Barve, Carolyn M Matthews, E Colin Koon, Thomas P Heffernan, Bruce Fine, Elizabeth Grosen, Melanie K Bergman, Evelyn L Fleming, Leslie R DeMars,[...]. Gynecol Oncol 2016
53
14

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.
Wei-Ting Hwang, Sarah F Adams, Emin Tahirovic, Ian S Hagemann, George Coukos. Gynecol Oncol 2012
379
14

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Robert L Coleman, Mark F Brady, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Joan L Walker, Byoung-Gie Kim, Keiichi Fujiwara, Krishnansu S Tewari, David M O'Malley,[...]. Lancet Oncol 2017
279
14

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, John K Chan, Minal A Barve, Jonathan Oh, Devansu Tewari, Peter C Morris, Erin E Stevens, Justin N Bottsford-Miller,[...]. Lancet Oncol 2020
23
14

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Tom Walsh, Silvia Casadei, Ming K Lee, Christopher C Pennil, Alex S Nord, Anne M Thornton, Wendy Roeb, Kathy J Agnew, Sunday M Stray, Anneka Wickramanayake,[...]. Proc Natl Acad Sci U S A 2011
611
14

Wise Management of Ovarian Cancer: On the Cutting Edge.
Stergios Boussios, Christos Mikropoulos, Eleftherios Samartzis, Peeter Karihtala, Michele Moschetta, Matin Sheriff, Afroditi Karathanasi, Agne Sadauskaite, Elie Rassy, Nicholas Pavlidis. J Pers Med 2020
39
14

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
14

BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Andrea Mafficini, Michele Simbolo, Alice Parisi, Borislav Rusev, Claudio Luchini, Ivana Cataldo, Elena Piazzola, Nicola Sperandio, Giona Turri, Massimo Franchi,[...]. Oncotarget 2016
53
9


Germline mutations in Thai patients with nonmucinous epithelial ovarian cancer.
Tarinee Manchana, Prasit Phowthongkum, Chinachote Teerapakpinyo. World J Clin Oncol 2019
4
50

Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
Marieke Arts-de Jong, Geertruida H de Bock, Christi J van Asperen, Marian J E Mourits, Joanne A de Hullu, C Marleen Kets. Eur J Cancer 2016
43
9

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Richard T Penson, Ricardo Villalobos Valencia, David Cibula, Nicoletta Colombo, Charles A Leath, Mariusz Bidziński, Jae-Weon Kim, Joo Hyun Nam, Radoslaw Madry, Carlos Hernández,[...]. J Clin Oncol 2020
77
9

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Amit M Oza, Anna V Tinker, Ana Oaknin, Ronnie Shapira-Frommer, Iain A McNeish, Elizabeth M Swisher, Isabelle Ray-Coquard, Katherine Bell-McGuinn, Robert L Coleman, David M O'Malley,[...]. Gynecol Oncol 2017
150
9


Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
Wenhui Li, Di Shao, Lei Li, Ming Wu, Shuiqing Ma, Xianjie Tan, Sen Zhong, Fengming Guo, Zhe Wang, Mingzhi Ye. J Ovarian Res 2019
14
14

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
Xin Yang, Goska Leslie, Alicja Doroszuk, Sandra Schneider, Jamie Allen, Brennan Decker, Alison M Dunning, James Redman, James Scarth, Inga Plaskocinska,[...]. J Clin Oncol 2020
120
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.